Predictive value of NT-proBNP for cardioversion in a new onset atrial fibrillation

European Journal of Emergency Medicine

Volumn 18, Issue 3, 2011, Pages 157-161

  Buccelletti, Francesco ^a   Gilardi, Emanuele ^a   Marsiliani, Davide ^a   Carroccia, Annarita ^a   Silveri, Nicolò Gentiloni ^a   Franceschi, Francesco ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

arrhythmia; atrial fibrillation; B type natriuretic peptide; cardioversion; likelihood ratio; prognostic value

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; CARDIOVERSION; CONTROLLED STUDY; EMERGENCY WARD; FEMALE; HEART ATRIUM FIBRILLATION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINUS RHYTHM;

AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; COHORT STUDIES; ELECTRIC COUNTERSHOCK; EMERGENCY SERVICE, HOSPITAL; FEMALE; HEART RATE; HUMANS; LOGISTIC MODELS; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 79955875221     PISSN: 09699546     EISSN: 14735695     Source Type: Journal    
DOI: 10.1097/MEJ.0b013e328342f2bf     Document Type: Article

References (19)

1. Ryder KM, Benjamin EJ. Epidemiology and significance of atrial fibrillation. Am J Cardiol 1999; 84:131-138. (Pubitemid 29528003)
2. Betts T, Mitchell A. Is rate more important than rhythm in treating atrial fibrillation? Yes/No. BMJ 2006; 339:664-665.
3. Therkelsen SK, Groenning BA, Kjaer A, Svendsen JH, Boje Jensen G. ANP and BNP in atrial fibrillation before and after cardioversion and their relationship to cardiac volume and function. Int J Cardiol 2008; 127:396-399. (Pubitemid 351885074)
4. Wozakowska-Kaplon B. ANP and B-type peptide: twins or kins? A different predictive value in atrial fibrillation; Natriuretic peptides: useful biomarkers in predicting the possibility of restoration and maintenance of sinus rhythm in patients with atrial fibrillation undergoing cardioversion? (IJC-D-09-01605). Int J Cardiol 2009 [Epub ahead of print].
5. Thejus J, Francio J. N-terminal pro-brain natriuretic peptide and atrial fibrillation. Indian Pacing and Electrophysiol J 2009; 106:91-94.
6. Mollmann H, Weber M, Elsasser A, Nef H, Dill T, Rixe J, et al. NT-proBNP predicts rhythm stability after cardioversion of lone atrial fibrillation. Circ J 2008; 72:921-925. (Pubitemid 351879912)
7. Danicek V, Theodorovich N, Bar-Chaim S, Miller A, Vered Z, Koren-Morag N, et al. Sinus rhythm restoration after atrial fibrillation: the clinical value of N-terminal proBNP measurements. Pacing Clin Electrophysiol 2008; 31:955-960.
8. Buob A, Jung J, Siaplaouras S, Neuberger HR, Mewis C. Discordant regulation of CRP and NT-proBNP plasma levels after electrical cardioversion of persistent atrial fibrillation. Pacing Clin Electrophysiol 2006; 29:559-563. (Pubitemid 43886605)
9. Beck-da-Silva L, de Bold A, Fraser M, Williams K, Haddad H. Brain natriuretic peptide predicts successful cardioversion in patients with atrial fibrillation and maintenance of sinus rhythm. Can J Cardiol 2004; 20:1245-1248. (Pubitemid 39545560)
10. Sanna T, Sonaglioni A, Pieroni M, Russo AD, Pelargonio G, Casella M, et al. Baseline NT-proBNP levels and arrhythmia recurrence in outpatients undergoing elective cardioversion of persistent atrial fibrillation: a survival analysis. Indian Pacing Electrophysiol J 2009; 9:15-24.
11. Shin DI, Jaekel K, Schley P, Sause A, Muller M, Fueth R, et al. Plasma levels of NT-proBNP in patients with atrial fibrillation before and after electrical cardioversion. Z Kardiol 2005; 94:795-800. (Pubitemid 43029746)
12. Inoue S, Murakami Y, Sano K, Katoh H, Shimada T. Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail 2000; 6:92-96. (Pubitemid 30439442)
13. Goetze JP, Friis-Hansen L, Rehfeld JF, Nilsson B, Svendsen JH. Atrial secretion of B-type natriuretic peptide. Eur Heart J 2006; 27:1648-1650. (Pubitemid 44025348)
14. De Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362:316-322. (Pubitemid 36936846)
15. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e257-e354. (Pubitemid 44252297)
16. Weingart S, Wyere P. Emergency medicine decision-making. Part I. New York: McGraw-Hill; 2006.
17. Asselbergs FW, Van den Berg MP, Bakker SJ, Signorovitch JE, Hillege HL, Van Gilst WH, Van Veldhuisen DJ. N-terminal pro B-type natriuretic peptide levels predict newly detected atrial fibrillation in a population-based cohort. Neth Heart J 2008; 16:73-78. (Pubitemid 351489572)
18. Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 2006; 92:843-849. (Pubitemid 43799232)
19. Bettencourt PM. Clinical usefulness of B-type natriuretic peptide measurement: present and future perspectives. Heart 2005; 91:1489-1494. (Pubitemid 41531838)